JP2003518115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003518115A5 JP2003518115A5 JP2001547093A JP2001547093A JP2003518115A5 JP 2003518115 A5 JP2003518115 A5 JP 2003518115A5 JP 2001547093 A JP2001547093 A JP 2001547093A JP 2001547093 A JP2001547093 A JP 2001547093A JP 2003518115 A5 JP2003518115 A5 JP 2003518115A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- carbon atoms
- chirally pure
- isomer
- oxadiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000004432 carbon atom Chemical group C* 0.000 claims 24
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims 22
- -1 Nitro, cyano, hydroxy, tert-butyl Chemical group 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 4
- 125000005293 bicycloalkoxy group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 4
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical group N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 2
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- RSZRNOGQARDDFO-UHFFFAOYSA-N 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]-4-methylisoindole-1,3-dione Chemical compound COC1=CC=C(C(CC=2OC=NN=2)N2C(C3=C(C)C=CC=C3C2=O)=O)C=C1OC1CCCC1 RSZRNOGQARDDFO-UHFFFAOYSA-N 0.000 claims 1
- VDLRFAGUSUZOBF-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]-4-methylisoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CC=2OC=NN=2)N2C(C3=C(C)C=CC=C3C2=O)=O)=C1 VDLRFAGUSUZOBF-UHFFFAOYSA-N 0.000 claims 1
- BDWWTCKFRDSMRX-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]benzo[e]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CC=2OC=NN=2)N2C(C3=C4C=CC=CC4=CC=C3C2=O)=O)=C1 BDWWTCKFRDSMRX-UHFFFAOYSA-N 0.000 claims 1
- UOQMOWITZGWSCW-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]isoindole-1,3-dione Chemical group C1=C(OC)C(OCC)=CC(C(CC=2OC=NN=2)N2C(C3=CC=CC=C3C2=O)=O)=C1 UOQMOWITZGWSCW-UHFFFAOYSA-N 0.000 claims 1
- DCXXFNKDFYYSDI-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-3h-isoindol-1-one Chemical compound C1=C(OC)C(OCC)=CC(C(CC=2OC(C)=NN=2)N2C(C3=CC=CC=C3C2)=O)=C1 DCXXFNKDFYYSDI-UHFFFAOYSA-N 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 208000020670 canker sore Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000005588 protonation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/470,203 | 1999-12-21 | ||
| US09/470,203 US6326388B1 (en) | 1999-12-21 | 1999-12-21 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| PCT/US2000/034457 WO2001046183A1 (en) | 1999-12-21 | 2000-12-19 | SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-α LEVELS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003518115A JP2003518115A (ja) | 2003-06-03 |
| JP2003518115A5 true JP2003518115A5 (https=) | 2005-06-09 |
| JP4806151B2 JP4806151B2 (ja) | 2011-11-02 |
Family
ID=23866662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001547093A Expired - Fee Related JP4806151B2 (ja) | 1999-12-21 | 2000-12-19 | 置換１，３，４−オキサジアゾールおよびＴＮＦαレベルの減少方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6326388B1 (https=) |
| EP (3) | EP1462449B9 (https=) |
| JP (1) | JP4806151B2 (https=) |
| KR (2) | KR100832499B1 (https=) |
| CN (1) | CN1413211A (https=) |
| AT (3) | ATE441644T1 (https=) |
| AU (1) | AU782168B2 (https=) |
| CA (1) | CA2394615C (https=) |
| DE (3) | DE60042902D1 (https=) |
| ES (3) | ES2333011T3 (https=) |
| FI (1) | FI121708B (https=) |
| HK (1) | HK1050522B (https=) |
| MX (1) | MXPA02006084A (https=) |
| NO (1) | NO323449B1 (https=) |
| NZ (1) | NZ529009A (https=) |
| PT (1) | PT1242413E (https=) |
| TW (2) | TW200733960A (https=) |
| WO (1) | WO2001046183A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| NZ334148A (en) * | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
| ATE374609T1 (de) | 2000-11-30 | 2007-10-15 | Childrens Medical Center | Synthese von 4-aminothalidomid enantiomeren |
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| EP2258363A1 (en) | 2002-05-17 | 2010-12-08 | Celgene Corporation | Compositions for treatment of cancers |
| KR20050043923A (ko) * | 2002-09-16 | 2005-05-11 | 알콘 매뉴팩츄어링, 리미티드 | 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도 |
| CN1713905A (zh) * | 2002-10-15 | 2005-12-28 | 细胞基因公司 | 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药 |
| US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| MXPA05004777A (es) * | 2002-11-06 | 2005-07-22 | Celgene Corp | Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos. |
| TW200501945A (en) | 2002-11-06 | 2005-01-16 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| NZ540546A (en) * | 2002-11-18 | 2008-03-28 | Celgene Corp | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| EP1581205A1 (en) * | 2002-11-18 | 2005-10-05 | Celgene Corporation | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| BR0317885A (pt) * | 2002-12-30 | 2005-12-06 | Celgene Corp | Composto, isÈmeros s e r enantiomericamente puros do mesmo, composição farmacêutica e métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa, de tratar ou prevenir mds, de tratar doença mieloproliferativa, angiogênese indesejada, câncer, uma doença, inflamação dos pulmões, depressão, distúrbio pulmonar obstrutivo crÈnico, doença inflamatória do intestino, dermatite atópica, psorìase, doença de crohn, artrite reumatóide, asma, eslcerose múltipla e doença cardìaca em um mamìfero e de tratar, prevenir ou controlar a sìndrome de dor regional complexa |
| US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| KR20060124607A (ko) * | 2003-11-06 | 2006-12-05 | 셀진 코포레이션 | 암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물 |
| US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
| US20060004043A1 (en) | 2003-11-19 | 2006-01-05 | Bhagwat Shripad S | Indazole compounds and methods of use thereof |
| US20080213213A1 (en) * | 2004-04-14 | 2008-09-04 | Zeldis Jerome B | Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione |
| MXPA06012279A (es) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
| US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| WO2006050057A2 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using pde4 modulators for treatment and management of central nervous system injury |
| US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| US7893045B2 (en) | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| WO2009149191A2 (en) | 2008-06-03 | 2009-12-10 | University Of Rochester | Methods of treating inflammatory intestinal disease and managing symptoms thereof |
| EP2344479B1 (en) * | 2008-09-23 | 2015-04-08 | Georgetown University | 1,2-benzisothiazolinone and isoindolinone derivatives |
| US8563580B2 (en) | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
| EP2395995A1 (en) | 2009-02-10 | 2011-12-21 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
| AU2010254149B2 (en) * | 2009-05-29 | 2014-08-21 | Merck Sharp & Dohme Llc | Radiolabeled PDE10 inhibitors |
| MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
| EP2583098B1 (en) | 2010-06-15 | 2018-08-08 | Celgene Corporation | Biomarkers for the treatment of psoriasis |
| WO2013025897A1 (en) | 2011-08-16 | 2013-02-21 | Georgetown University | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives |
| WO2015175956A1 (en) | 2014-05-16 | 2015-11-19 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
| AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| HUE065109T2 (hu) | 2015-06-26 | 2024-05-28 | Celgene Corp | Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása |
| WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
| CN107698484B (zh) * | 2017-11-13 | 2020-05-19 | 广东中科药物研究有限公司 | 一种来那度胺的衍生物的制备方法与应用 |
| AU2019254962C1 (en) * | 2018-04-17 | 2023-04-27 | Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd | Isoindole derivatives |
| WO2020060963A1 (en) * | 2018-09-18 | 2020-03-26 | Alxerion Biotech Corp. | 1, 3, 4-oxadiazole derivatives and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4173652A (en) | 1976-12-18 | 1979-11-06 | Akzona Incorporated | Pharmaceutical hydroxamic acid compositions and uses thereof |
| SE434638B (sv) | 1980-06-06 | 1984-08-06 | Lekemedelsfabriken Medica Ab | Nya terapeutiska verdefulla taurinderivat och deras framstellning |
| US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
| US5747501A (en) * | 1992-04-07 | 1998-05-05 | Pfizer, Inc. | Indole derivatives |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| FR2712886B1 (fr) * | 1993-11-26 | 1996-01-05 | Synthelabo | Dérivés de 1,3,4-oxadiazol-2(3H)-one, leur préparation et leur application en thérapeutique. |
| JPH07278125A (ja) * | 1994-03-31 | 1995-10-24 | Nippon Chemiphar Co Ltd | アルキレンジアミン誘導体 |
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| CA2227237C (en) | 1995-07-26 | 2005-12-13 | Pfizer Inc. | N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| US5670526A (en) * | 1995-12-21 | 1997-09-23 | Otsuka Pharmaceutical Co., Ltd. | 1,3,4-oxadiazoles |
| PT871439E (pt) | 1996-01-02 | 2004-08-31 | Aventis Pharma Inc | Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo) |
| NZ334148A (en) | 1996-08-12 | 2001-12-21 | Celgene Corp | 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels |
| JP2921760B2 (ja) * | 1997-05-21 | 1999-07-19 | 日本たばこ産業株式会社 | フタルイミド誘導体及びそれら誘導体を含んでなる医薬 |
| CA2309204A1 (en) * | 1997-11-26 | 1999-06-03 | Dupont Pharmaceuticals Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists |
| PL342060A1 (en) * | 1998-01-29 | 2001-05-21 | Bristol Myers Squibb Co | Derivatives of 1,3,4-oxadiaxolone |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
-
1999
- 1999-12-21 US US09/470,203 patent/US6326388B1/en not_active Expired - Lifetime
-
2000
- 2000-12-11 TW TW095138294A patent/TW200733960A/zh unknown
- 2000-12-11 TW TW089125923A patent/TWI280961B/zh not_active IP Right Cessation
- 2000-12-19 MX MXPA02006084A patent/MXPA02006084A/es active IP Right Grant
- 2000-12-19 KR KR1020027007983A patent/KR100832499B1/ko not_active Expired - Fee Related
- 2000-12-19 DE DE60042902T patent/DE60042902D1/de not_active Expired - Lifetime
- 2000-12-19 ES ES04003830T patent/ES2333011T3/es not_active Expired - Lifetime
- 2000-12-19 EP EP04003830A patent/EP1462449B9/en not_active Expired - Lifetime
- 2000-12-19 EP EP00986568A patent/EP1242413B1/en not_active Expired - Lifetime
- 2000-12-19 DE DE60016029T patent/DE60016029T2/de not_active Expired - Lifetime
- 2000-12-19 PT PT00986568T patent/PT1242413E/pt unknown
- 2000-12-19 ES ES00986568T patent/ES2233488T3/es not_active Expired - Lifetime
- 2000-12-19 DE DE60045320T patent/DE60045320D1/de not_active Expired - Lifetime
- 2000-12-19 CA CA002394615A patent/CA2394615C/en not_active Expired - Fee Related
- 2000-12-19 ES ES04020108T patent/ES2356238T3/es not_active Expired - Lifetime
- 2000-12-19 AT AT04003830T patent/ATE441644T1/de not_active IP Right Cessation
- 2000-12-19 KR KR1020077008998A patent/KR20070049688A/ko not_active Ceased
- 2000-12-19 NZ NZ529009A patent/NZ529009A/en not_active IP Right Cessation
- 2000-12-19 WO PCT/US2000/034457 patent/WO2001046183A1/en not_active Ceased
- 2000-12-19 HK HK03101117.3A patent/HK1050522B/en not_active IP Right Cessation
- 2000-12-19 CN CN00817536A patent/CN1413211A/zh active Pending
- 2000-12-19 AU AU22785/01A patent/AU782168B2/en not_active Ceased
- 2000-12-19 AT AT00986568T patent/ATE282612T1/de active
- 2000-12-19 JP JP2001547093A patent/JP4806151B2/ja not_active Expired - Fee Related
- 2000-12-19 AT AT04020108T patent/ATE489996T1/de not_active IP Right Cessation
- 2000-12-19 EP EP04020108A patent/EP1510518B1/en not_active Expired - Lifetime
-
2002
- 2002-06-18 NO NO20022937A patent/NO323449B1/no not_active IP Right Cessation
- 2002-06-19 FI FI20021192A patent/FI121708B/fi not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003518115A5 (https=) | ||
| JP2003518060A5 (https=) | ||
| CA2394615A1 (en) | Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels | |
| RU2394826C2 (ru) | Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы | |
| CN100372836C (zh) | 新的免疫治疗剂亚酰胺/酰胺类 | |
| RU2010101212A (ru) | Бром-фенил замещенные тиазолилдигидропиримидины | |
| ES2278467T3 (es) | Fenetilsulfonas sustituidas y metodo para reducir los niveles de tnf-alfa y pde-iv. | |
| ES2282147T3 (es) | Derivados de isoindolina farmaceuticamente activos. | |
| JP2001526269A5 (https=) | ||
| JP6511430B2 (ja) | がんの治療のための化合物および組成物 | |
| JP2002506861A5 (https=) | ||
| CA2321920A1 (en) | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | |
| JP2004536869A5 (https=) | ||
| JP2005535586A5 (https=) | ||
| JP2004535447A5 (https=) | ||
| JP2005537248A5 (https=) | ||
| JP2004509113A5 (https=) | ||
| JP2001526222A5 (https=) | ||
| CN115209900A (zh) | 用于预防或治疗其中存在kras突变和活化ron的癌症的药物组合物 | |
| JP2006525944A5 (https=) | ||
| JP2023521351A5 (https=) | ||
| JP2004529925A5 (https=) | ||
| HRP20090468T1 (hr) | Urea antagonisti p2y1 receptora korisni u liječenju trombotičkih stanja | |
| RU2009131454A (ru) | Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств | |
| KR20070086919A (ko) | 치환된 아실히드록삼산과 ＴＮＦａ의 함량을 감소시키는방법 |